PIVEKIMAB SUNIRINE
UNII L15LO3W1XX

Substance Identification & Data

This profile provides standardized clinical and technical data for Pivekimab Sunirine, uniquely identified by the FDA Unique Ingredient Identifier (UNII) L15LO3W1XX.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2417174-95-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

L15LO3W1XX

CAS Registry Number

2417174-95-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PIVEKIMAB SUNIRINE

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

L15LO3W1XX

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C184834

National Cancer Institute reference terminology for clinical and research data.

INN ID

11695

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-169

Identifier assigned by the United States Adopted Names Council.

Substance Type

PIVEKIMAB SUNIRINE

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Pivekimab Sunirine. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

PIVEKIMAB SUNIRINE

Pivekimab Sunirine-PVZY

Common Names & Synonyms

AN ANTIBODY DRUG CONJUGATE CONSISTING OF HUMANIZED ANTI-CD123 ANTIBODY G4723A LINKED WITH DNA ALKYLATING AGENT DGN549C FOR AML AND OTHER CD123-POS. MALIGNANCIES

HUMANISED IgG1 KAPPA ANTI-CD123 MONOCLONAL ANTIBODY G4723AB - SULFONATED DGN549-C CONJUGATE IMGN632

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS IL3RA (INTERLEUKIN 3 RECEPTOR SUBUNIT ALPHA, INTERLEUKIN 3 RECEPTOR, ALPHA (LOW AFFINITY), CD123)), MONOCLONAL ANTIBODY, CONJUGATED WITH SULFONATED DGN549-C, A CYTOTOXIC INDOLOBENZODIAZEPINE DIMER BONDED TO A PROTEASE-CLEAVABLE MALEIMIDOETHYLAMINO-ADIPYL-ALA-ALA LINKER; GAMMA1 HEAVY CHAIN (1-450) (VH (HOMO SAPIENS IGHV1-46*01 (80.6%)-(IGHD)-IGHJ4*01 (100%), CDR-IMGT (8.8.14) (26-33.51-58.97-110)) (1-121)-HOMO SAPIENS IGHG1*01, G1M17,1 (CH1 K120 (218) (122-219), HINGE 1-15 (220-234), CH2 (235-344), CH3 D12 (360), L14 (362), S122>C (446) (345-449), CHS K2>DEL (450)) (122-450)), (224-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') (V-KAPPA MUSMUS/HOMSAP (MUS MUSCULUS IGKV14-111*01 (83.2%)-IGKJ2*03 (83.3%) S120>Q (100), L124>V (104)/HOMO SAPIENS IGKV1-16*01 (82.1%)-IGKJ2*01 (91.7%) L124>V (104), CDR-IMGT (6.3.9) (27-32.50-52.89-97)) (1'-107')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')); DIMER (230-230'':233-233'')-BISDISULFIDE, PRODUCED IN A CHINESE HAMSTER OVARY (CHO)-K1 CELL LINE, GLYCOFORM ALFA; CONJUGATED AT THE SULFUR ATOMS OF CYS446 AND CYS446'' WITH APPROXIMATELY TWO (3.XI.)-1-(2-(6-(((2S)-1-(((2S)-1-(3-((((12S,12AS)-8-METHOXY-6-OXO-12-SULFO-11,12,12A,13-TETRAHYDRO-6H-INDOLO(2,1-C)(1,4)BENZODIAZEPIN-9-YL)OXY)METHYL)-5-((((12AS)-8-METHOXY-6-OXO-11,12,12A,13-TETRAHYDRO-6H-INDOLO(2,1-C)(1,4)BENZODIAZEPIN-9-YL)OXY)METHYL)ANILINO)-1-OXOPROPAN-2-YL)AMINO)-1-OXOPROPAN-2-YL)AMINO)-6-OXOHEXANAMIDO)ETHYL)-2,5-DIOXOPYRROLIDIN-3-YL (SUNIRINE) GROUPS

PIVEKIMAB SUNIRINE [USAN]

Pivekimab sunirine [WHO-DD]

pivekimab sunirine [INN]